Older Familial Hypercholesterolemia Patients with COVID-19

Gerontology. 2021;67(5):608-610. doi: 10.1159/000514447. Epub 2021 Mar 18.

Authors

Alpo Vuorio^{1

2}, Petri T Kovanen³, Timo E Strandberg^{4

5}

Affiliations

¹ Mehiläinen, Airport Health Center, Vantaa, Finland, alpo.vuorio@gmail.com.
² Department of Forensic Medicine, University of Helsinki, Helsinki, Finland, alpo.vuorio@gmail.com.
³ Wihuri Research Institute, Helsinki, Finland.
⁴ University of Helsinki and Helsinki University Hospital, Helsinki, Finland.
⁵ Center for Life Course Health Research, University of Oulu, Oulu, Finland.

PMID: 33735871
DOI: 10.1159/000514447

No abstract available

Keywords: Atherosclerosis; COVID-19; Old; PCSK9 inhibitors; Statins.

MeSH terms

Age Factors
Aged
COVID-19 / epidemiology*
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use
Hyperlipoproteinemia Type II / complications*
Hyperlipoproteinemia Type II / drug therapy
Middle Aged
PCSK9 Inhibitors
Proprotein Convertase 9 / therapeutic use

Substances

Hydroxymethylglutaryl-CoA Reductase Inhibitors
PCSK9 Inhibitors
PCSK9 protein, human
Proprotein Convertase 9